A Molecular Biology And Phase II Study Of Lapatinib (GW572016) In Pediatric Patients With Recurrent Or Refractory Medulloblastoma, Malignant Glioma Or Ependymoma.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Lapatinib (Primary)
Indications Astrocytoma; Brain cancer; Ependymoma; Glioblastoma; Glioma; Gliosarcoma; Medulloblastoma; Oligodendroglioma; Primitive neuroectodermal tumours
Focus Therapeutic Use

03 Feb 2012 Actual patient number changed from 42 to 52 as reported by ClinicalTrials.gov.
10 Nov 2010 Actual end date (July 2010) added as reported by ClinicalTrials.gov.
10 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com